Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial
Xiaotao Qu(The Affiliated Yongchuan Hospital of Chongqing Medical University), Alexander V. Louie(London Health Sciences Centre), Sashendra Senthi(Alfred Health), Neil Kopek(McGill University Health Centre), Stephen Harrow(Beatson West of Scotland Cancer Centre), Stewart Gaede(London Health Sciences Centre), George Rodrigues(London Health Sciences Centre), Liam Mulroy(Nova Scotia Cancer Centre), Gregory S. Zaric(Western University), Suresh Senan(Amsterdam Neuroscience), Ava John‐Baptiste(Western University), David A. Palma(Western University), Yujie Chen(Army Medical University), Robert Olson(BC Cancer Agency), Andrew Warner(London Health Sciences Centre), Anand Swaminath(Juravinski Cancer Centre), Devin Schellenberg(Surrey Place Centre), Mitchell Liu
International Journal of Radiation Oncology*Biology*Physics
December 10, 2020
Cited by 41
Related Papers
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.3k
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k
Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer
|New England Journal of Medicine|2007|1.1k